AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...

AbbVie and Gubra ink license agreement to develop an amylin analog for the treatment of obesity: North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] AbbVie and Gubra A ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...